Adaptimmune Phase 2 gets positive responses in sarcoma; reporting at ASCO

 Data will support BLA filing for afamitresgene autoleucel next year -

- Responses observed across a broad range of antigen expression -

- Initial safety and durability are encouraging -

Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, will report initial data from its Phase 2 SPEARHEAD-1 trial, with afamitresgene autoleucel (afami-cel, formerly ADP-A2M4), at the American Society of Clinical Oncology (ASCO) congress. Full abstracts were released online today. Data will be presented in an oral presentation by Dr. Sandra D’Angelo of the Memorial Sloan Kettering Cancer Center (Abstract #11504) on June 4th.

https://finance.yahoo.com/news/two-complete-responses-response-rate-210000957.html